Warner Chilcott Announces FDA Approval of DELZICOL; CASMED Announces Recent Publication of Study Using FORE-SIGHT Cerebral Tissue Oximetry Print
By Staff and Wire Reports   
Tuesday, 05 February 2013 20:03
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 5, 2013.

Warner Chilcott plc (Nasdaq: WCRX) announced the United States FDA has approved its new 400 mg mesalamine product indicated for the treatment of ulcerative colitis. The product will be marketed as DELZICOL™ (mesalamine) 400 mg delayed-release capsules. The Company anticipates that it will commercially launch DELZICOL in March 2013.


======


CAS Medical Systems, Inc. (NASDAQ:CASM)
announced the recent pre-publication of a key study showing otherwise unrecognized cerebral desaturation events occurred in more than half of post-surgical ICU patients.

In a study led by Steven Greenberg, M.D. from the University of Chicago and the North Shore University Health System in Evanston, Illinois, clinicians monitored post-cardiac surgery patients during their first six hours in the post-surgical intensive care unit. The study, "Cerebral desaturation events in the intensive care unit following cardiac surgery", pre-published by the Journal of Critical Care and available at http://dx.doi.org/10.1016/j.jcrc.2012.09.004 , revealed that 53% of the 53 patients studied suffered from low levels of brain oxygen (oxygen desaturations) that were otherwise unrecognized by standard monitoring. More than half of those brain oxygen desaturation events lasted more than one hour. The mortality rate amongst the group that experienced brain oxygen desaturations was 5 out of 28, or 18%, while no one in the non-desaturation group died.

"We believe that this study is the first of its kind, largely because few clinicians thought that unrecognized cerebral desaturations would occur after the conclusion of surgery," Dr. Greenberg reported. "We were quite surprised to discover the high incidence of cerebral desaturations, the length of time that these patients spent in a desaturated state, and the rate of mortality amongst the cerebral desaturation group."

"The ability of the FORE-SIGHT Oximeter to provide highly accurate measurements of cerebral oximetry without the need for a baseline or a pre-induction value proved to be crucial in both the design and successful conduct of this study," Dr. Greenberg continued. "And while more study is necessary, these data suggest that there may be an important role for cerebral oximetry monitoring in the ICU."

"One of our key goals is to continue to generate published clinical data in support of the use of FORE-SIGHT Tissue Oximetry in a broad category of clinical applications where brain protection is critically important," said Thomas M. Patton, President and CEO of CASMED. "This study revealed a new and important application of FORE-SIGHT Oximetry to empower clinicians to improve the care of their patients."



Also Tuesday:



ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
, a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013, at 10:00 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City.

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX)
today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 10:00a.m. Eastern time in the Duke of Windsor Salon at The Waldorf=Astoria Hotel in New York.

Allergan, Inc. (NYSE: AGN)
today announced operating results for the quarter ended December 31, 2012.

Atossa Genetics, Inc. (NASDAQ: ATOS)
, The Breast Health Company™, announced today that Kyle Guse, CFO and General Counsel, will present the Company's business model, products and services, and investment thesis at the FSX Dallas Conference at the Ritz Carlton Dallas Hotel in Dallas, Texas, on Friday, February 8, 2013, beginning at 9:49 am Central Time.

BioDelivery Sciences International, Inc. (Nasdaq: BDSI)
announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 15th Annual BIO CEO and Investor Conference.

Can-Fite BioPharma (TASE: CFBI; OTC: CANFY)
a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases,announced today that it has successfully completed its public offering of common shares and warrants that trade on the Tel-Aviv Stock Exchange with the participation of Israeli, US and European investors.

China Botanic Pharmaceutical Inc. (AMEX: CBP)
(formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, announced today that on January 31, 2013, the Company received a notice of failure to satisfy continued listing standards (the "Letter") from the NYSE MKT LLC (the "Exchange").

Covidien (NYSE: COV)
, a leading global provider of healthcare products, today announced that Mallinckrodt plc intends to apply to list its ordinary shares on the New York Stock Exchange (NYSE) to trade under the symbol MNK.

Healthcare Services Group, Inc. (NASDAQ: HCSG)
reported that revenues for the three months ended December 31, 2012 increased approximately 11% to $277,039,000 compared to $250,239,000 for the same 2011 period.

IEC Electronics Corp. (NYSE MKT: IEC)
announced its unaudited results for the first quarter of fiscal 2013 ending December 28, 2012.

Mesa Laboratories, Inc. (NASDAQ: MLAB)
(we, us, our, "Mesa" or the "Company") today reported an 18 percent increase in revenues for the third quarter ended December 31, 2012.

MMRGlobal, Inc. (OTCQB: MMRF)
("MMR") today announced that it has been brought to the Company's attention that Governments, both state and federal, in Australia, through the National E-Health Transition Authority (NEHTA), appear to be infringing on patents (including Australian patent numbers 2006202057 and 2008202401) and other Intellectual Property (collectively, the "MMRIP") issued to MyMedicalRecords.com, Inc., a wholly owned subsidiary of MMRGlobal.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB)
, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it recently participated in a focused panel session at the 6th International Symposium on Metastasis in Head and Neck Cancer held in Marburg, Germany. Lymphoseek® (technetium Tc 99m tilmanocept) Injection and initial clinical experience data from one site participating in the Lymphoseek head and neck cancer clinical trial, NEO3-06, were discussed during a satellite symposium focused on Sentinel Lymph Node (SLN) biopsy in Head and Neck Cancer.

NuVasive, Inc. (NASDAQ: NUVA)
, a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is pleased to announce that The Better Way Back®, a NuVasive supported patient education program, has reached over 1,000 active patient ambassadors nationwide.

Origin Agritech Limited (NASDAQ GS: SEED)
("Origin", or the "Company"), a technology-focused supplier of crop seeds in China, today announced unaudited financial results for the first quarter ended December 31, 2012.

Pegasus Pharmaceuticals (PINKSHEETS: PGUZ)
has introduced to the pharmaceutical industry an innovative product that effectively controls fungi/mold cells and prevents long-term spore growth at PDA (Parenteral Drug Association) conferences in Chicago and Phoenix.

Synthetic Biologics, Inc. (NYSE MKT: SYN)
, a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its Chief Executive Officer, Jeffrey Riley, will present at the 2013 BIO CEO & Investor Conference.

Techne Corporation's (NASDAQ: TECH)
financial results for the second quarter and six months ended December 31, 2012

TelVue® Corporation (PINKSHEETS: TEVE)
, the innovation leader in Television and Internet Broadcasting for cable and telco operators, media companies and communities is pleased to be joining the National Cable Television Cooperative (NCTC) as a Provider of Digital and IP Broadcast Servers and Cloud Video Services.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
announced today enrollment of the first patient in the MODERATO study – a Phase IV clinical study designed to evaluate the effect of AZILECT® (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

Therapeutic Solutions International, Inc. (OTCQB: TSOI)
announced today it will host an investor conference call at 4:15 p.m. Eastern Standard Time on Tuesday, February 12.

WOUND MANAGEMENT TECHNOLOGIES (OTCQB: WNDM | WNDM.PK)
finished 2012 with fourth quarter customer sales revenues of approximately $440,000 (an increase of 23% over the previous quarter) and annual sales revenues of approximately $1.18M.

YaFarm Technologies, Inc. (PINKSHEETS: YFRM)
(YaFarm, or the Company) is pleased to announce that it has signed a definitive agreement to acquire the Integrative Stem Cell Institute (the ISCI).

YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM)
(the "Company" or "YM") is pleased to announce that the Supreme Court of Nova Scotia has issued a final order approving the previously announced plan of arrangement (the "Arrangement") involving the Company, Gilead Sciences, Inc. ("Gilead") and 3268218 Nova Scotia Limited, a wholly-owned subsidiary of Gilead (the "Purchaser").

Zalicus Inc. (NASDAQ: ZLCS)
, a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Zalicus management will present at the 2013 BIO CEO & Investor Conference at 9:00 p.m. ET on Tuesday, February 12, 2013 at the Waldorf Astoria in New York.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus